Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Amgen Inc. is currently conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease.’ The study aims to demonstrate that maridebart cafraglutide is more effective than a placebo in reducing body weight by at least 5% in participants with obesity.
The intervention being tested is maridebart cafraglutide, a drug administered subcutaneously. It is designed to aid in weight reduction and is being tested in various doses against a placebo.
The study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. Both participants and investigators are blinded to the treatment allocations, which is crucial for unbiased results. The primary purpose of the study is treatment-focused.
The study began on June 13, 2025, and its primary completion is yet to be announced. The last update was submitted on July 30, 2025. These dates are important for tracking the progress and expected timelines for results.
This update could potentially influence Amgen’s stock performance positively if the results show significant efficacy, as it would position the company strongly in the obesity treatment market. Investors should watch for competitor developments in obesity treatments, as these could impact market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.